EC alleges EU merger procedural rules were breached in Sigma-Aldrich acquisition

6 July 2017
mergers-acquisitions-big

The European Commission has sent three separate Statements of Objections to Germany’s Merck KGaA (MRK: DE) and its subsidiary Sigma-Aldrich, General Electric and Canon alleging they breached EU merger rules: General Electric, and Merck and Sigma-Aldrich by providing incorrect or misleading information; Canon by implementing a merger before notification and clearance.

The current investigations are limited to the assessment of breaches of the European Union merger procedural rules and will not have an impact on the Commission decisions approving the three mergers, which will remain effective.

Commissioner Margrethe Vestager, in charge of competition policy, said: "We need companies to work with us to ensure fast and predictable merger control, to the benefit of both companies and consumers. But we can only do our job well if we can rely on cooperation from the companies concerned – they must obtain our approval before they implement their transactions and the information they supply us must be correct and complete."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical